PYTHON

Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe

Retrieved on: 
Tuesday, July 25, 2023

The agreement builds on the existing prostate cancer PSMA-targeted PET imaging collaboration between Curium and Lantheus with an exclusive licensing and development agreement for AI-powered quantitative analysis and standardized reporting of PSMA PET/CT image assessments.

Key Points: 
  • The agreement builds on the existing prostate cancer PSMA-targeted PET imaging collaboration between Curium and Lantheus with an exclusive licensing and development agreement for AI-powered quantitative analysis and standardized reporting of PSMA PET/CT image assessments.
  • Under the terms of the agreement, EXINI’s deep learning platform will be tailored to meet the specific needs of the European market.
  • With the expanding treatment options in prostate cancer, including PSMA RLT, there is increasing demand for efficient, standardized quantitative assessment of PSMA disease burden.
  • Our partnership with Curium expands the pool of patient data informing our AI algorithm and enables more widespread access to our software.”

Curium Announces Publication of [18F]DCFPyL Versus [18F]Fluoromethylcholine Results From European Phase III Study (PYTHON Trial)

Retrieved on: 
Friday, July 21, 2023

PARIS, July 21, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the publication of the results of its European, multicenter, prospective cross-over clinical trial which compared [18F] piflufolastat ([18F]DCFPyL) versus [18F]fluoromethylcholine PET/CT in patients with first biochemical recurrence of prostate cancer.

Key Points: 
  • PARIS, July 21, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the publication of the results of its European, multicenter, prospective cross-over clinical trial which compared [18F] piflufolastat ([18F]DCFPyL) versus [18F]fluoromethylcholine PET/CT in patients with first biochemical recurrence of prostate cancer.
  • The results of the PYTHON trial were published online ahead of print in the European Journal of Nuclear Medicine and Molecular Imaging in June 2023.
  • The PYTHON Study (NCT04734184) was a Phase III, European, multicenter, prospective cross-over trial, to evaluate and compare the detection rates, impact on patient management and safety profiles of [18F]DCFPyL and [18F]fluoromethylcholine, in patients with first biochemical recurrence after initial definitive therapy with curative intent.
  • This study successfully met the primary endpoint.

ENGINE Launch Announcement

Retrieved on: 
Thursday, August 4, 2022

A large library of Walmart (Retail Link, Luminate) content is available inside ENGINE, as well as integration with syndicated datasets by Nielsen, IRI, and others.

Key Points: 
  • A large library of Walmart (Retail Link, Luminate) content is available inside ENGINE, as well as integration with syndicated datasets by Nielsen, IRI, and others.
  • ENGINE is already working with several industry leading CPG customers, and major retailers.
  • Where a customer traditionally needed 3 or 4 different software platforms, now all they need is ENGINE, this is going to be very disruptive.
  • ENGINE is based in Northwest Arkansas (3335 S. Market St, Rogers, AR 72758) and recently expanded into a new office building next to Theos.

Curium Announces the Submission of its Marketing Authorization Application for [18F]-DCFPyL to the European Medicines Agency

Retrieved on: 
Monday, June 27, 2022

Phase III PYTHON clinical trial results to be presented at the 35th Annual Congress of the European Association of Nuclear Medicine, October 15-19, 2022 in Barcelona, Spain

Key Points: 
  • Phase III PYTHON clinical trial results to be presented at the 35th Annual Congress of the European Association of Nuclear Medicine, October 15-19, 2022 in Barcelona, Spain
    PARIS, June 27, 2022 (GLOBE NEWSWIRE) -- Curium the worlds leading nuclear medicine company, today announced the submission of its Marketing Authorization Application for [18F]-DCFPyL to the European Medicines Agency.
  • The submission comes two months after completing its Phase III PYTHON trial of [18F]-DCFPyL and follows two US pivotal trials OSPREY and CONDOR by Progenics Pharmaceuticals, Inc., a Lantheus company.
  • In the U.S., [18F]-DCFPyL was approved by the FDA in May of 2021 and is commercially available as PYLARIFY (Piflufolastat F 18 Injection) and sold by Lantheus.
  • Benoit Woessmer, PET Europe Chief Executive Officer at Curium added: With the completion of the PYTHON clinical trial and the submission of our Marketing Authorization Application to the European Medicines Agency, Curium demonstrates its continued dedication and commitment to developing life-saving diagnostic solutions for cancer patients around the world.